Pharmacology of vasopressin antagonists

Lisa C. Costello-Boerrigter, Guido Boerrigter, John C Jr. Burnett

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Congestive heart failure (CHF) is characterized by fluid and water retention, which frequently is a therapeutic challenge. Most conventional diuretics act primarily as saluretics, i.e. they inhibit renal tubular electrolyte reabsorption, which due to osmotic pressure promotes excretion of isotonic fluid. Arginine vasopressin (AVP) via the V1A receptor vasoconstricts and via the V2 receptor promotes water reabsorption in the renal collecting duct by inserting aquaporin-2 water channels into the luminal membrane. Novel V2 receptor antagonists act as powerful aquaretics, i.e. they excrete free water. We review the pharmacology of non-selective V1A/V2 receptor antagonists and selective V2 receptor antagonists currently in clinical development.

Original languageEnglish (US)
Pages (from-to)75-82
Number of pages8
JournalHeart Failure Reviews
Volume14
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Vasopressin Receptors
Pharmacology
Water
Aquaporin 2
Aquaporins
Arginine Vasopressin
Osmotic Pressure
Diuretics
Electrolytes
Heart Failure
Kidney
Membranes
Antidiuretic Hormone Receptor Antagonists
Therapeutics

Keywords

  • Aquaretic
  • Arginine vasopressin
  • Heart failure
  • Pharmacology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacology of vasopressin antagonists. / Costello-Boerrigter, Lisa C.; Boerrigter, Guido; Burnett, John C Jr.

In: Heart Failure Reviews, Vol. 14, No. 2, 2009, p. 75-82.

Research output: Contribution to journalArticle

Costello-Boerrigter, LC, Boerrigter, G & Burnett, JCJ 2009, 'Pharmacology of vasopressin antagonists', Heart Failure Reviews, vol. 14, no. 2, pp. 75-82. https://doi.org/10.1007/s10741-008-9108-8
Costello-Boerrigter, Lisa C. ; Boerrigter, Guido ; Burnett, John C Jr. / Pharmacology of vasopressin antagonists. In: Heart Failure Reviews. 2009 ; Vol. 14, No. 2. pp. 75-82.
@article{05356e5866594ef2a2d45f34d6b7b049,
title = "Pharmacology of vasopressin antagonists",
abstract = "Congestive heart failure (CHF) is characterized by fluid and water retention, which frequently is a therapeutic challenge. Most conventional diuretics act primarily as saluretics, i.e. they inhibit renal tubular electrolyte reabsorption, which due to osmotic pressure promotes excretion of isotonic fluid. Arginine vasopressin (AVP) via the V1A receptor vasoconstricts and via the V2 receptor promotes water reabsorption in the renal collecting duct by inserting aquaporin-2 water channels into the luminal membrane. Novel V2 receptor antagonists act as powerful aquaretics, i.e. they excrete free water. We review the pharmacology of non-selective V1A/V2 receptor antagonists and selective V2 receptor antagonists currently in clinical development.",
keywords = "Aquaretic, Arginine vasopressin, Heart failure, Pharmacology",
author = "Costello-Boerrigter, {Lisa C.} and Guido Boerrigter and Burnett, {John C Jr.}",
year = "2009",
doi = "10.1007/s10741-008-9108-8",
language = "English (US)",
volume = "14",
pages = "75--82",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Pharmacology of vasopressin antagonists

AU - Costello-Boerrigter, Lisa C.

AU - Boerrigter, Guido

AU - Burnett, John C Jr.

PY - 2009

Y1 - 2009

N2 - Congestive heart failure (CHF) is characterized by fluid and water retention, which frequently is a therapeutic challenge. Most conventional diuretics act primarily as saluretics, i.e. they inhibit renal tubular electrolyte reabsorption, which due to osmotic pressure promotes excretion of isotonic fluid. Arginine vasopressin (AVP) via the V1A receptor vasoconstricts and via the V2 receptor promotes water reabsorption in the renal collecting duct by inserting aquaporin-2 water channels into the luminal membrane. Novel V2 receptor antagonists act as powerful aquaretics, i.e. they excrete free water. We review the pharmacology of non-selective V1A/V2 receptor antagonists and selective V2 receptor antagonists currently in clinical development.

AB - Congestive heart failure (CHF) is characterized by fluid and water retention, which frequently is a therapeutic challenge. Most conventional diuretics act primarily as saluretics, i.e. they inhibit renal tubular electrolyte reabsorption, which due to osmotic pressure promotes excretion of isotonic fluid. Arginine vasopressin (AVP) via the V1A receptor vasoconstricts and via the V2 receptor promotes water reabsorption in the renal collecting duct by inserting aquaporin-2 water channels into the luminal membrane. Novel V2 receptor antagonists act as powerful aquaretics, i.e. they excrete free water. We review the pharmacology of non-selective V1A/V2 receptor antagonists and selective V2 receptor antagonists currently in clinical development.

KW - Aquaretic

KW - Arginine vasopressin

KW - Heart failure

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=63449087902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449087902&partnerID=8YFLogxK

U2 - 10.1007/s10741-008-9108-8

DO - 10.1007/s10741-008-9108-8

M3 - Article

C2 - 18766438

AN - SCOPUS:63449087902

VL - 14

SP - 75

EP - 82

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -